May 6, 2009 — The US Food and Drug Administration (FDA) has granted accelerated approval for bevacizumab (Avastin, Genentech) for use in patients with glioblastoma that has progressed despite previous ...
Prospective Multicenter Study Evaluating a Combined Circulating Tumor DNA and Circulating Tumor RNA Liquid Biopsy in Metastatic Non–Small Cell Lung Cancer (LIQUIK) The use of bevacizumab in ...
University of Kentucky Markey Cancer Center researchers have discovered a genetic biomarker that could help identify patients with glioblastoma most likely to benefit from the cancer drug bevacizumab.
The Avastin in Glioblastoma (AVAglio) study (BO21990) was a randomized, double-blind, placebo-controlled trial sponsored by F. Hoffmann–La Roche and designed by the AVAglio steering committee (see the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results